~~<i id='090C999DAF'><strike id='090C999DAF'><tt id='090C999DAF'><pre id='090C999DAF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：explore 2025-09-06 05:59:57 - browse：12594

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Study: Spinal cord stimulation helps patients with paralysis walk again

Wikipedia

focus

hotspot

explore

hotspot

leisure time

AdobeJustweeksafterNovoNordiskannouncedthatitsobesitydrugWegovycuttheriskofheartcomplicationsinamajo

WSS

Meadows told special counsel he could not recall Trump ever declassifying Mar

Trans patients at the end of life deserve respect and dignity

American taxpayers paid $1.8 trillion in health care costs in 2022

Life science postdocs should get big pay hike, NIH panel says

Study: Spinal cord stimulation helps patients with paralysis walk again

How to make over

leisure time

knowledge

Featured Speakers

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

How the drug

Trump demands the U.S. pay no more for drugs than other countries … again

How the first Native Hawaiian psychiatrist helped diversify medicine

Guidelines to prevent youth baseball injuries need more muscle

People can get long Covid without testing positive for virus: Study

Medicare proposal to cover medical devices draws a mixed reaction

National associations that represent hospice owe an apology

The high cost of giving birth even with insurance

Former Pear Therapeutics executives start new VC firm

focus

Medicare Advantage coverage denials need scrutiny, senators say

Merck to acquire Harpoon Therapeutics for $680 million

Stories you might have missed in 2023: health, science, medicine

Vivek Ramaswamy made waves in the debate, much as in biotech

California store owner shot dead in dispute over displaying Pride flag: Police

Former Pear Therapeutics executives start new VC firm

hotspot

explore

hotspot

leisure time